Welcome to LookChem.com Sign In|Join Free
  • or
4-bromo-2-isopropyl-6-nitrophenol is a chemical with a specific purpose. Lookchem provides you with multiple data and supplier information of this chemical.

127293-44-1

Post Buying Request

127293-44-1 Suppliers

Recommended suppliers

  • Product
  • FOB Price
  • Min.Order
  • Supply Ability
  • Supplier
  • Contact Supplier

127293-44-1 Usage

Check Digit Verification of cas no

The CAS Registry Mumber 127293-44-1 includes 9 digits separated into 3 groups by hyphens. The first part of the number,starting from the left, has 6 digits, 1,2,7,2,9 and 3 respectively; the second part has 2 digits, 4 and 4 respectively.
Calculate Digit Verification of CAS Registry Number 127293-44:
(8*1)+(7*2)+(6*7)+(5*2)+(4*9)+(3*3)+(2*4)+(1*4)=131
131 % 10 = 1
So 127293-44-1 is a valid CAS Registry Number.

127293-44-1Relevant academic research and scientific papers

Proline-Catalyzed Cyclization Reaction for the Synthesis of Naphthostyrils: Application to the Total Synthesis of Prioline

Park, Kyeong-Yong,Song, Ha-Jeong,Heo, Jung-Nyoung

, p. 3197 - 3205 (2015/11/03)

A new method for the synthesis of naphthostyrils is described. In this method, a sequential Stille coupling and proline-catalyzed cyclization procedure is employed for the reaction of 4-bromooxindoles and β-tributylstannyl-α,β-unsaturated ketones. The uti

Production Method of Nitrogen-Containing Fused Ring Compounds

-

, (2010/11/30)

[Problems] The present invention provides a superior production method and a superior purification method of compounds effective for the treatment or prophylaxis of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like. [Means] A compound represented by the following formula [2] or a pharmaceutically acceptable salt thereof can be produced by reacting a compound represented by the following formula [3] or a salt thereof with a compound represented by the following formula [4], a salt thereof or a reactive derivative thereof. Moreover, crystallization of a compound represented by the formula [2] can be performed with industrially superior workability, and high quality crystals of a compound represented by the formula [2] can be obtained. wherein each symbol is as defined in the description.

Pharmaceutical Compositions Comprising Nitrogen-Containing Fused Ring Coumpounds

-

, (2009/01/20)

[Problems] The present invention provides pharmaceutical composition which is effective for the prophylaxis or treatment of pathology showing involvement of uric acid (hyperuricemia, gouty tophus, acute gout arthritis, chronic gout arthritis, gouty kidney, urolithiasis, renal function disorder, coronary arterial disease, ischemic heart disease and the like) and the like, and is superior in the time-course stability and dissolution property (disintegration property). [Solving Means] The pharmaceutical composition of the present invention is a pharmaceutical composition comprising a nitrogen-containing fused ring compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, and one or more pharmaceutically acceptable additives, wherein the nitrogen-containing fused ring compound or a pharmaceutically acceptable salt thereof is not in contact with a basic additive: wherein each symbol is as described in the specification.

Nitrogen-containing fused ring compounds and use thereof

-

Page/Page column 90, (2010/11/25)

A URAT1 activity inhibitor containing a nitrogen-containing fused ring compound represented by the following formula [1]: wherein each symbol is as defined in the description. The present invention is useful for the prophylaxis or treatment of pathology showing involvement of uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urolithiasis, renal function disorder, coronary artery disease, ischemic heart disease and the like.

Carboxylic Acid Compounds and Use Thereof

-

Page/Page column 44, (2010/11/28)

Provision of a superior URAT1 activity inhibitor effective for the treatment and the like of a pathology involving uric acid, such as hyperuricemia, gouty tophus, acute gouty arthritis, chronic gouty arthritis, gouty kidney, urinary lithiasis, renal dysfunction, coronary heart disease, ischemic cardiac diseases and the like. A URAT1 activity inhibitor containing a compound represented by the following formula [1] or a pharmaceutically acceptable salt thereof, or a solvate thereof as an active ingredient: [image] wherein each symbol is as defined in the specification.

Process for producing nitrophenol compound

-

, (2008/06/13)

An improved industrial process for producing a compound of the general formula: STR1 wherein R is an alkyl group having 1 to 4 carbon atoms which comprises reacting a compound of the general formula: STR2 wherein R is as defined above with nitrous acid in

Post a RFQ

Enter 15 to 2000 letters.Word count: 0 letters

Attach files(File Format: Jpeg, Jpg, Gif, Png, PDF, PPT, Zip, Rar,Word or Excel Maximum File Size: 3MB)

1 Customer Service

What can I do for you?
Get Best Price

Get Best Price for 127293-44-1